Immunovaccine Inc is going to be the solution to End Cancer?

Immunotherapy is going to be the solution to put an end to cancer.  We have discovered a new way to deliver messages to immune system. We are co-devel …

Solution to End Cancer

© 2020 www.B-TV.com. All Rights Reserved.

Immunotherapy is going to be the solution to put an end to cancer. We have discovered a new way to deliver messages to immune system. We are co-developing our products with two partners, Merck and Insight. It has the potential to transform the way we work with our immune system.We believe that the key to leveraging the power of human immunity resides in the way we communicate with our immune system. Modern medicine has created access to technologically advanced targets. Proteins, peptides, DNA/RNA vaccines—that can be used to encode directives to our immune system. But those commands are secondary, as our immune systems have already evolved over millions of years to precisely and powerfully recognize and respond to a wide variety of danger signals.For more information on Immunovaccine Inc (IMV.TO) please fill out the form.

No items found.

You might also like

Metals & Mining
January 26, 2026

CEO Clips – ONGold Resources: Advancing High-Grade Gold & Strategic Critical Minerals in Canada

ONGold Resources is building a diversified portfolio of projects positioned to benefit from rising global demand for both precious and critical minerals.

This is some text inside of a div block.
Metals & Mining
January 26, 2026

ONGold Resources: Focused on Gold, Copper & Critical Minerals

ONGold Resources is advancing a growing portfolio of projects across Ontario and Manitoba, centered on gold, copper, and strategically important critical minerals.

This is some text inside of a div block.
Sitka Gold: Intensifies Discovery Momentum with Yukon Drill Program and Strategic Advancements
Metals & Mining
January 22, 2026

Sitka Gold: Intensifies Discovery Momentum with Yukon Drill Program and Strategic Advancements

This is some text inside of a div block.
Subscribe and receive the investor Info